

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 January 2025 (23.01.2025)



(10) International Publication Number
WO 2025/019318 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) C07D 417/14 (2006.01)
A61K 31/404 (2006.01) C07D 471/22 (2006.01)
A61K 31/426 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/037809

(22) International Filing Date:

12 July 2024 (12.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/526,781 14 July 2023 (14.07.2023) US
63/618,731 08 January 2024 (08.01.2024) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **JIANG, Jingjing**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **MALDONATO, Benjamin**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SALMAN, Zeena**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SINGH, Mallika**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WANG, Zhengping**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CHANG, Stephanie, S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GUSTAFSON, W., Clay**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

17 April 2025 (17.04.2025)

(54) Title: METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER



(57) Abstract: The disclosure features methods of treating RAS disorders using safe and effective doses of Compound (A), or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound (A), or a pharmaceutically acceptable salt thereof, and additional therapeutic agent.

WO 2025/019318 A3